Article Text

Download PDFPDF
Why are anogenital warts diagnoses decreasing in the UK: bivalent human papillomavirus (HPV) vaccine cross-protection or failure to examine?
  1. Emily Clarke1,
  2. Christopher Board2,
  3. Natasha Patel2,
  4. Lindsay Atkinson2,
  5. Hugh Tulloch2,
  6. Raj Patel1,2
  1. 1 Department of Genitourinary Medicine, Royal South Hants Hospital, Southampton, UK
  2. 2 Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK
  1. Correspondence to Dr Emily Clarke, Department of Genitourinary Medicine, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK; emilyrclarke{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rates of first episode anogenital warts diagnoses in the UK have fallen from a peak prevalence of 151.9/100 000 population in 2008 to 139.1/100 000 in 2012, an 8% reduction.1 In Australia, the quadrivalent human papillomavirus (HPV) vaccination strategy (against HPV16 and 18 causing cervical cancer, and HPV6 and 11 causing anogential warts) has led to an unexpected reduction in warts diagnoses in unvaccinated males and older people.2 This has contributed to speculation that the UK decrease in warts may be due to cross-protection from the bivalent HPV vaccination programme (against HPV16 and 18 …

View Full Text


  • Contributors EC: literature search, study design, data collection, data analysis, data interpretation and writing. CB, NP and LA: data collection and data analysis. HT: literature search and writing. RP: Study design and writing.

  • Competing interests None.

  • Ethics approval Solent NHS Trust approved this service evaluation.

  • Provenance and peer review Not commissioned; internally peer reviewed.